儿童脑肿瘤幸存者中枢源性嗜睡症的患病率、危险因素及治疗反应
研究回顾性分析2336例儿童脑肿瘤患者,39例诊断为中枢源性嗜睡症/发作性睡病,患病率为1670/10万。中线肿瘤位置(OR 4.6)和抗癫痫药物使用(OR 11)与嗜睡症/发作性睡病相关,后颅窝肿瘤位置降低风险(OR 0.1)。37例接受兴奋剂治疗,报告觉醒度和学业表现改善。
要点
- 儿童脑肿瘤幸存者中枢源性嗜睡症/发作性睡病患病率为1670/10万
- 中线肿瘤位置(OR 4.6)和抗癫痫药物使用(OR 11)与嗜睡症/发作性睡病相关
- 37例接受兴奋剂治疗,报告觉醒度和学业表现改善
核心结论
- 儿童脑肿瘤幸存者中枢源性嗜睡症/发作性睡病患病率高于一般人群。
- 肿瘤位置和放疗剂量可能是危险因素,兴奋剂报告有益。
研究设计与样本
- 回顾性研究,纳入2000年1月至2015年4月在本机构治疗的2336例脑肿瘤患者。
- 使用标准PSG/MSLT标准诊断嗜睡症/发作性睡病。
- 将39例嗜睡症/发作性睡病患者与2-3例无嗜睡症/发作性睡病的幸存者按诊断时年龄、性别和自肿瘤诊断起的时间进行匹配。
主要发现
- 2336例脑肿瘤患者中39例诊断为嗜睡症/发作性睡病,患病率为1670/10万。
- 嗜睡症/发作性睡病诊断距肿瘤诊断的中位时间为6.1年(范围0.4-13.2),距颅脑放疗的中位时间为4.7年(范围-1.5至10.4)。
- 中线肿瘤位置(OR 4.6,CI 1.7-12.2,p=0.002)和抗癫痫药物使用(OR 11,CI 2.4-54)与嗜睡症/发作性睡病相关。
- 放疗剂量>30 Gy呈边缘显著趋势(OR 1.8,CI 0.9-3.6);后颅窝肿瘤位置降低风险(OR 0.1,CI 0.04-0.5,p=0.002)。
- 抗癫痫药物使用也与中线肿瘤位置相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daytime sleepiness is recognized in childhood brain tumor survivors. Our objective was to determine prevalence, risk factors for PSG/MLST proven hypersomnia/narcolepsy, and response to stimulants in childhood brain tumor survivors. Standard PSG/MSLT criteria were used to diagnose hypersomnia/narcolepsy. Medical records of brain tumor survivors having undergone a PSG/MSLT were reviewed for the diagnostic code of hypersomnia/narcolepsy. Survivors with hypersomnia/narcolepsy were matched with 2-3 survivors without reported hypersomnia/narcolepsy by age at tumor diagnosis, gender, and time from tumor diagnosis. Between January 2000 to April 2015, 39 of the 2336 brain tumor patients treated at our institution were diagnosed with hypersomnia/narcolepsy for a prevalence rate of 1670/100,000. Hypersomnia/narcolepsy was diagnosed at a median of 6.1 years (range 0.4-13.2) from tumor diagnosis and 4.7 years (range - 1.5 to 10.4) from cranial radiation. Midline tumor location (OR 4.6, CI 1.7-12.2, p = 0.002) and anti-epilepsy drug (AED) use (OR 11, CI 2.4-54) correlated with hypersomnia/narcolepsy while radiation dose > 30 Gray trended towards significance (OR 1.8, CI 0.9-3.6); posterior fossa tumor location reduced the risk (OR 0.1, CI 0.04-0.5, p = 0.002). AED use also correlated with midline tumor location. Thirty-seven survivors were treated with stimulants and reported improved wakefulness and school performance [response rate CI 0.97 (0.86-0.99) and 0.83 (0.65-0.94)]. Prevalence of hypersomnia/narcolepsy among childhood brain tumor survivors was higher than the general population. Tumor location and radiation dose were possible risk factors, and stimulants were reported to be beneficial.
引用
- Khan RB, Merchant TE, Sadighi ZS, et al. Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol. 2017. PMID: 29116485. doi:10.1007/s11060-017-2662-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。